| Objective:To investigate the clinical effectiveness and clinical value of neoadjuvant chemotherapy in gastric cancer with stage Ⅲ treatment, to provide clinical evidence for neoadjuvant chemotherapy.Method:Take a retrospective analysis methods, based on inclusion and exclusion criteria,155 patients with stage Ⅲ gastric cancer were selected from among the cases seen at the Affiliated Tumor Hospital of Guangxi Medical University from June 1,2009 to May 31,2014. These patients had been treated with neoadjuvant chemotherapy. In the end we analyzed the results of patients treated with neoadjuvant chemotherapy.Results:After neoadjuvant chemotherapy, the patients with gastric cancer there were 11 patients achieved complete remission (CR),79 patients achieved a partial response (PR),50 patients with the stable disease (SD). Through the neoadjuvant chemotherapy, we can find that the effective rate of neoadjuvant chemotherapy for the patients with gastric cancer is 58.06%, the probability of radical surgery for patients is 67.74%, the probability of palliative resection is 9.68%. After neoadjuvant chemotherapy in patients with gastric cancer, serum CEA positive rate dropped to 25.81% from 70.96%, the value of serum CEA decreased to 6.149 ± 8.393ng/ml from 35.105 ± 79.683ng/ml. The main side effects of chemotherapy are nausea and vomiting, diarrhea, leukopenia and peripheral neuritis, with rates of 85.8%,65.2%,66.5% and 49.7%, all patients for neoadjuvant chemotherapy were well tolerated. The complication rate of radical surgery is 17.14%.Conclusion:1. Neoadjuvant chemotherapy for stage Ⅲ gastric cancer can reduce the tumor stage and lower serum CEA concentration.2. Neoadjuvant chemotherapy can improve the surgical resection rate of stage Ⅲ gastric cancer patients.3. Neoadjuvant chemotherapy treatment for patients with stage Ⅲ gastric cancer is a safe and effective. |
PDF Full Text Request